Viloxazine (Qelbree): A Faster Strattera?
The Carlat Child Psychiatry Report, Volume 12, Number 3&4, April 2021
Topics: ADHD Attention Deficit Hyperactivity Disorder | ADHD-RS-5 | CGI | Clinical Global Impressions | Post-hoc Analysis ADHD Rating Scale-5 | Qelbree | Viloxazine | Weiss Functional Impairment Rating Scale-Parent (WFIRS-P)
Joshua Feder, MD, and Talia Puzantian, PharmD, BCPP.
Dr. Feder and Dr. Puzantian have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
As of April, 2021, we have a brand new non-stimulant medication approved for treatment of ADHD in the US. Are we excited? Does this represent an advance over other efforts to produce effective non-stimulant medications for ADHD, or is it another instance of ‘me too’? What does the supporting research tell us? And what side effects do we need to watch out for? Read and learn.